P2RY2 and neoplasm: Combination treatment of subcutaneous xenografts of AsPC-1 or BxPC-3 cells with the P2Y2 antagonist AR-C together with gemcitabine significantly decreased tumor weight and resulted in increased survival compared to placebo or gemcitabine monotherapy control (Hu et al., 2019).